A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
Phase 3
Completed
NCT06041217
| Condition | Overweight, Obesity |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Novo Nordisk A/S |
|---|
| Status | Completed |
|---|
| Enrollment | 242 participants |
|---|
| Interventions | Semaglutide |
|---|
| Start date | Sep 15, 2023 |
|---|
| Completion date | Apr 2, 2025 |
|---|
| Results posted | May 18, 2026 |
|---|
Summary
This study will look at how the investigational dose of semaglutide works in helping people with excess body weight, to lose weight. This study will compare the weight loss in people taking semaglutide to people taking "dummy" medicine (placebo). The study will last for about 1 year. The participants will have 12 visits at the clinic and 3 remote visits by phone calls with the study doctor or staff.
Change in Body Weight (%)
Baseline (week 0), end of treatment (week 44) · Percentage change in body weight
| Semaglutide 2.4 mg | -12.2 ± 8.2 Percentage change in body weight |
|---|
| Placebo | -2.2 ± 5.4 Percentage change in body weight |
|---|
| p-value | <0.0001 |
|---|
| Treatment difference | -9.87 (95% CI -11.78–-7.96) |
|---|
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal to (≥) 5% (Yes/No)
At end of treatment (week 44) · Participants
| Semaglutide 2.4 mg | 128 Participants |
|---|
| Placebo | 19 Participants |
|---|
| Semaglutide 2.4 mg | 31 Participants |
|---|
| Placebo | 59 Participants |
|---|
| p-value | <0.0001 |
|---|
| Odds Ratio (OR) | 14.83 (95% CI 7.42–29.63) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.